Company intelligence / Profile preview
SHINKEI Therapeutics
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
SHINKEI Therapeutics focuses on developing therapies for central nervous system disorders by repurposing existing pharmaceutical products using the FDA’s streamlined regulatory pathway. Their lead candidate targeting VMAT2 for movement disorders has reached early Phase I clinical trials. Additional programs are in preclinical development targeting motor neuron disease, epilepsy, and emotional lability. The company aims to improve drug administration routes to enhance compliance and reduce side effects.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on SHINKEI Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHINKEI Therapeutics.